Fig. 4
Impact of mature DCs and CD20+ B cells on the immune contexture of HGSCs and associated anticancer immune response. a Representative images of DC-LAMP immunostaining. Scale bar = 50 μm. b Density of CD20+ B cells in the tumor stroma and tumor nest in DC-LAMPLo versus DC-LAMPHi HGSCs (n = 81). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. c Density of CD8+ T cells in DC-LAMPLo/CD20Lo, DC-LAMPLo/CD20Hi, DC-LAMPHi/CD20Lo, DC-LAMPHi/CD20Hi HGSCs. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. d Relative expression levels of CCR4, CXCL14, CCR7, CCL5, CCR2, CCL19, CCL22, CCR1, CCL18, CCRL2, CXCR3, CCR10, CCR5 and CXCL9 in 9 DC-LAMPHi/CD20Hi versus 9 DC-LAMPLo/CD20Lo HGSCs, as determined by RNA-Seq and IHC. Benjamin-Hochberg correction was used for RNA-Seq data. e Percentage of IFN-γ+ and PRF1+ cells among CD8+CD3+ T cells from 10 DC-LAMPLo and 10 DC-LAMPHi samples. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. f, g, h, i OS of HGSC patients who did not receive neoadjuvant chemotherapy, upon stratification based on median density of CD20+ cells plus CD8+ cells (g), CD20+ cells plus DC-LAMP+ cells (h), or median density of all 3 parameters (i). Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk are reported